23.88
price up icon5.43%   1.23
after-market Handel nachbörslich: 23.88
loading
Schlusskurs vom Vortag:
$22.65
Offen:
$22.61
24-Stunden-Volumen:
669.37K
Relative Volume:
0.91
Marktkapitalisierung:
$693.38M
Einnahmen:
$17.16M
Nettoeinkommen (Verlust:
$-163.62M
KGV:
-3.9276
EPS:
-6.08
Netto-Cashflow:
$-121.61M
1W Leistung:
+2.75%
1M Leistung:
+9.24%
6M Leistung:
+78.74%
1J Leistung:
-0.25%
1-Tages-Spanne:
Value
$22.43
$24.69
1-Wochen-Bereich:
Value
$21.87
$24.86
52-Wochen-Spanne:
Value
$12.21
$41.31

Anaptysbio Inc Stock (ANAB) Company Profile

Name
Firmenname
Anaptysbio Inc
Name
Telefon
858-362-6295
Name
Adresse
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Name
Mitarbeiter
136
Name
Twitter
@anaptysbio
Name
Nächster Verdiensttermin
2024-11-08
Name
Neueste SEC-Einreichungen
Name
ANAB's Discussions on Twitter

Vergleichen Sie ANAB mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ANAB
Anaptysbio Inc
23.88 693.38M 17.16M -163.62M -121.61M -6.08
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-04 Hochstufung H.C. Wainwright Neutral → Buy
2025-02-04 Eingeleitet Wolfe Research Outperform
2024-12-11 Herabstufung H.C. Wainwright Buy → Neutral
2024-12-02 Herabstufung BTIG Research Buy → Neutral
2024-07-22 Eingeleitet H.C. Wainwright Buy
2024-07-19 Hochstufung JP Morgan Neutral → Overweight
2024-04-16 Eingeleitet Leerink Partners Outperform
2024-04-11 Eingeleitet Wells Fargo Overweight
2024-03-12 Hochstufung Wedbush Neutral → Outperform
2024-02-26 Eingeleitet BTIG Research Buy
2024-02-21 Eingeleitet Stifel Buy
2024-02-16 Eingeleitet Piper Sandler Overweight
2023-05-22 Hochstufung JP Morgan Underweight → Neutral
2023-05-18 Eingeleitet TD Cowen Outperform
2023-01-06 Herabstufung Raymond James Outperform → Mkt Perform
2022-11-01 Hochstufung Guggenheim Neutral → Buy
2022-09-19 Fortgesetzt H.C. Wainwright Buy
2022-09-13 Herabstufung Truist Buy → Hold
2022-09-01 Eingeleitet Raymond James Outperform
2022-03-22 Herabstufung Guggenheim Buy → Neutral
2021-06-22 Eingeleitet H.C. Wainwright Buy
2021-05-21 Eingeleitet UBS Neutral
2021-03-16 Hochstufung Truist Hold → Buy
2021-03-09 Herabstufung Wedbush Outperform → Neutral
2021-03-08 Herabstufung JP Morgan Overweight → Underweight
2021-02-11 Hochstufung JP Morgan Underweight → Overweight
2020-10-27 Hochstufung Wedbush Neutral → Outperform
2020-10-14 Hochstufung Guggenheim Neutral → Buy
2019-11-08 Herabstufung JP Morgan Overweight → Underweight
2019-11-08 Herabstufung Jefferies Buy → Hold
2019-11-08 Herabstufung SunTrust Buy → Hold
2019-11-08 Herabstufung Wedbush Outperform → Neutral
2019-06-21 Herabstufung Credit Suisse Outperform → Neutral
2019-06-21 Herabstufung Stifel Buy → Hold
2018-12-20 Eingeleitet H.C. Wainwright Buy
2018-11-21 Eingeleitet JP Morgan Overweight
2018-07-19 Eingeleitet Credit Suisse Outperform
2018-04-04 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2018-03-27 Bestätigt Stifel Buy
2018-03-06 Bestätigt Stifel Buy
2018-02-15 Bestätigt SunTrust Buy
2018-01-23 Bestätigt Credit Suisse Outperform
2017-11-15 Eingeleitet SunTrust Buy
2017-11-09 Eingeleitet Jefferies Buy
2017-10-11 Bestätigt RBC Capital Mkts Outperform
2017-09-15 Eingeleitet RBC Capital Mkts Outperform
Alle ansehen

Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten

pulisher
Jun 18, 2025

AnaptysBio, Inc. (NASDAQ:ANAB) Holdings Trimmed by Bank of America Corp DE - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Assenagon Asset Management S.A. Sells 89,273 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat

Jun 18, 2025
pulisher
Jun 17, 2025

AnaptysBio Holds 2025 Annual Stockholders Meeting - TipRanks

Jun 17, 2025
pulisher
Jun 12, 2025

FMR LLC Significantly Reduces Stake in AnaptysBio Inc - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Stocks With Rising Relative Price Strength: AnaptysBio - Investor's Business Daily

Jun 12, 2025
pulisher
Jun 11, 2025

JPMorgan Sees AnaptysBio (ANAB) as Undervalued Due to Rosnilimab - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Shareholders May Be More Conservative With AnaptysBio, Inc.'s (NASDAQ:ANAB) CEO Compensation For Now - simplywall.st

Jun 11, 2025
pulisher
Jun 10, 2025

New RA Drug Shown to Work, Be Safe - streetwisereports.com

Jun 10, 2025
pulisher
Jun 10, 2025

AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster Potential (NASDAQ:ANAB) - Seeking Alpha

Jun 10, 2025
pulisher
Jun 09, 2025

ANAB Schedules June 9 Conference Call with JPMorgan | ANAB Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Price Target at $42.38 - MarketBeat

Jun 09, 2025
pulisher
Jun 09, 2025

AnaptysBio (NASDAQ:ANAB) Shares Up 9.1%Should You Buy? - MarketBeat

Jun 09, 2025
pulisher
Jun 08, 2025

AnaptysBio (NASDAQ:ANAB) Trading Down 4.5%Time to Sell? - MarketBeat

Jun 08, 2025
pulisher
Jun 08, 2025

AnaptysBio (NASDAQ:ANAB) Upgraded by HC Wainwright to "Buy" Rating - MarketBeat

Jun 08, 2025
pulisher
Jun 07, 2025

AnaptysBio (NASDAQ:ANAB) Shares Gap UpHere's What Happened - MarketBeat

Jun 07, 2025
pulisher
Jun 06, 2025

AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement (NASDAQ:ANAB) - Seeking Alpha

Jun 06, 2025
pulisher
Jun 06, 2025

AnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

AnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Squarepoint Ops LLC - MarketBeat

Jun 05, 2025
pulisher
Jun 05, 2025

TD Cowen reiterates Buy rating on AnaptysBio stock following updated trial data - Investing.com Canada

Jun 05, 2025
pulisher
Jun 05, 2025

AnaptysBio (NASDAQ:ANAB) Upgraded to “Buy” at HC Wainwright - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

AnaptysBio (ANAB) Shares Drop Amid Trial Data Missteps - GuruFocus

Jun 05, 2025
pulisher
Jun 04, 2025

HC Wainwright & Co. Upgrades AnaptysBio (LSE:0HFQ) - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

J&J hurts AnaptysBio with anti-inflammatory data (ANAB:NASDAQ) - Seeking Alpha

Jun 04, 2025
pulisher
Jun 04, 2025

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point - Benzinga

Jun 04, 2025
pulisher
Jun 04, 2025

AnaptysBio (ANAB) Reveals Promising Phase 2b Results in Rheumato - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May - Benzinga

Jun 04, 2025
pulisher
Jun 04, 2025

AnaptysBio describes ‘JAK-like’ efficacy for PD-1 drug in rheumatoid arthritis - Endpoints News

Jun 04, 2025
pulisher
Jun 04, 2025

H.C. Wainwright upgrades AnaptysBio stock on positive trial data By Investing.com - Investing.com Canada

Jun 04, 2025
pulisher
Jun 04, 2025

Anaptys stock gains on arthritis drug data (ANAB:NASDAQ) - Seeking Alpha

Jun 04, 2025
pulisher
Jun 04, 2025

AnaptysBio’s Rosnilimab Shows ‘Best-in-Disease’ Profile in Phase 2b RA Trial - Insider Monkey

Jun 04, 2025
pulisher
Jun 04, 2025

Stifel analysts reiterate Buy rating for AnaptysBio stock after RA study - Investing.com UK

Jun 04, 2025
pulisher
Jun 04, 2025

HC Wainwright & Co. Upgrades AnaptysBio (ANAB) - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

AnaptysBio (ANAB) Stock Upgraded by HC Wainwright & Co. with New - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

AnaptysBio (ANAB) Stock Upgraded by HC Wainwright & Co. with New Target Price | ANAB Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

HC Wainwright Upgrades AnaptysBio to Buy From Neutral, $38 Price Target - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Stifel Reiterates Buy Rating on AnaptysBio (ANAB) - StreetInsider

Jun 04, 2025
pulisher
Jun 04, 2025

AnaptysBio (ANAB) Gets Boost from Positive Phase 2 Trial Data | ANAB Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

AnaptysBio reports promising Phase 2b trial results for RA drug By Investing.com - Investing.com India

Jun 04, 2025
pulisher
Jun 04, 2025

AnaptysBio Stock Jumps On Promising Rheumatoid Arthritis Drug Readout; Retail Traders Brace For Potential Offering - Investing.com India

Jun 04, 2025
pulisher
Jun 03, 2025

Transcript : AnaptysBio, Inc.Special Call - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

AnaptysBio Reports Positive Phase 2b Trial Results - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

AnaptysBio Reports Durable Responses, Favorable Safety for Rosnilimab in Arthritis Trial - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

AnaptysBio (ANAB) Reports Promising Results for Rosnilimab in Rheumatoid Arthritis | ANAB Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Anaptys Announces Positive Rosnilimab Data Updated Through Six M - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

AnaptysBio reports promising Phase 2b trial results for RA drug - Investing.com Australia

Jun 03, 2025
pulisher
Jun 03, 2025

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

New Rheumatoid Arthritis Drug Achieves JAK-Like Efficacy with Better Safety Profile in Phase 2b Trial - Stock Titan

Jun 03, 2025
pulisher
Jun 03, 2025

Millennium Management LLC Sells 185,049 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World

Jun 03, 2025

Finanzdaten der Anaptysbio Inc-Aktie (ANAB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Anaptysbio Inc-Aktie (ANAB) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
RENTON HOLLINGS
Director
Jun 18 '25
Sale
23.97
3,015
72,270
4,965
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):